GE HealthCare
GEHC
$68.86
-1.23%
GE HealthCare Technologies is a leading medical technology firm specializing in imaging, ultrasound, and patient care solutions, operating within the Medical - Devices industry. The company holds leading market share in imaging and ultrasound equipment, with a diversified portfolio across four segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The current investor narrative centers on the company's growth trajectory amid cost inflation pressures, as evidenced by a recent guidance cut due to $250 million in cost inflation, while the company continues to invest in innovation and navigate a competitive landscape. Attention is also focused on its ability to maintain margins and generate sustainable free cash flow in a challenging macroeconomic environment.…
GEHC
GE HealthCare
$68.86
Related headlines
Investment Opinion: Should I buy GEHC Today?
Based on the analysis, GEHC is rated a 'Buy' with a thesis that its undervaluation and leading market position provide a favorable risk/reward. The consensus recommendation is 'buy' with an average target of $82.50, implying ~20% upside. The stock's forward PE of 12.73x is well below the industry average of 22x, and revenue growth of 7.4% in Q1 2026 supports earnings expansion. Additionally, free cash flow of $1.52 billion and a net margin of 10.1% indicate solid profitability.
Sign up to view all
GEHC 12-Month Price Forecast
The AI assessment is neutral with medium confidence. GEHC's valuation is attractive, but the company faces significant near-term headwinds from cost inflation. The stock's low forward PE suggests the market expects strong earnings growth, which may be optimistic given the guidance cut. If the company can execute on cost management and deliver on growth, the stock could re-rate higher. However, any further negative surprises could lead to a downgrade to bearish. Key factors to watch are margin trends and revenue growth consistency.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on GE HealthCare's 12-month outlook, with a consensus price target around $82.50 and implied upside of +19.8% versus the current price.
Average Target
$82.50
0 analysts
Implied Upside
+19.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$70 - $96
Analyst target range
GEHC is covered by 18 analysts, with a consensus recommendation of 'buy' and a mean recommendation score of 1.74 (where 1 is strong buy and 5 is sell). The average target price is $82.50, implying an upside of approximately 19.8% from the current price of $68.86. The distribution of ratings is not provided, but the consensus leans bullish, with recent actions from firms like BTIG reiterating 'Buy' and Evercore ISI maintaining 'Outperform', while some neutral stances exist from UBS, JP Morgan, and Goldman Sachs (which downgraded from Buy to Neutral). The target price range spans from $70.00 low to $96.00 high, indicating a wide spread of 37% between the lowest and highest targets, reflecting high uncertainty about the company's future performance. The high target of $96 assumes strong execution on growth initiatives and margin recovery, while the low target of $70 suggests concerns about sustained cost inflation and competitive pressures. Recent downgrades by Goldman Sachs and UBS (from Sell to Neutral) suggest some analysts are becoming more cautious, but the overall buy consensus and upside potential indicate a moderately positive outlook.
Bulls vs Bears: GEHC Investment Factors
GEHC presents a mixed picture: strong market position and attractive valuation are offset by margin pressure from cost inflation and uneven execution. The bull case relies on the stock's low forward PE (12.73x) and analyst consensus upside of ~20%, while the bear case centers on the $250 million cost inflation hit and recent guidance cut. Currently, the bearish evidence is slightly stronger given the negative earnings revision and stock underperformance, but the valuation provides a margin of safety. The key tension is whether GEHC can offset cost inflation through pricing and productivity improvements; if it can, the stock is undervalued, but if not, further downside is possible.
Bullish
- Attractive Valuation with 20% Upside: GEHC trades at a trailing PE of 17.99x and forward PE of 12.73x, below the industry average of 22x. The average analyst target of $82.50 implies ~19.8% upside from the current price of $68.86, suggesting the stock is undervalued relative to its earnings potential.
- Strong Revenue Growth in Q1 2026: Q1 2026 revenue grew 7.41% YoY to $5.131 billion, rebounding from a decline in Q4 2025. This growth, driven by imaging and other segments, indicates improving demand and a recovery from prior softness.
- Healthy Profitability and Cash Flow: GEHC reported a net margin of 10.1% and operating margin of 13.4% in the latest quarter. Free cash flow TTM stands at $1.52 billion, providing ample liquidity for investments and shareholder returns.
- Leading Market Position in Imaging: GEHC holds leading market share in imaging and ultrasound equipment, with imaging contributing 45% of revenue. This competitive moat supports pricing power and long-term demand, especially as healthcare infrastructure spending grows.
Bearish
- Cost Inflation Pressures Margins: GEHC lowered its 2026 earnings guidance due to $250 million in cost inflation, which is difficult to offset given long sales cycles. This has pressured margins, with gross margin declining to 38.5% in Q1 2026 from 42.1% a year earlier.
- Stock Underperformed Market Significantly: GEHC is down 7.1% over the past year, while the S&P 500 gained 18.65%. The stock sits near the lower end of its 52-week range, reflecting persistent investor skepticism and negative momentum.
- High Debt Levels Increase Financial Risk: Debt-to-equity ratio is 0.96, indicating substantial leverage. Interest expenses of $96 million in Q1 2026 consume a notable portion of operating income, making the company sensitive to rising interest rates.
- Uneven Revenue Performance: Q4 2025 revenue fell to $4.674 billion from $5.319 billion in Q4 2024, a decline of 12.1%. This volatility suggests demand is inconsistent, possibly due to lumpy capital equipment purchases and macro uncertainty.
GEHC Technical Analysis
GEHC's price trend over the past year has been characterized by a significant downtrend, with the stock down 7.1% over the past year, underperforming the S&P 500's 18.65% gain. The current price of $68.86 sits at approximately 38% of its 52-week range (between $58.75 low and $89.77 high), indicating the stock is closer to its lows than highs, suggesting a bearish or value-oriented positioning. The stock has experienced a maximum drawdown of -32.53% from its highs, reflecting substantial volatility and investor caution.
Beta
0.82
0.82x market volatility
Max Drawdown
-32.5%
Largest decline past year
52-Week Range
$59-$90
Price range past year
Annual Return
-7.1%
Cumulative gain past year
| Period | GEHC Return | S&P 500 |
|---|---|---|
| 1m | -2.0% | -0.4% |
| 3m | +6.5% | +4.2% |
| 6m | -7.3% | +13.7% |
| 1y | -7.1% | +19.0% |
| ytd | -16.9% | +12.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GEHC Fundamental Analysis
GEHC's revenue trajectory shows moderate growth, with the most recent quarter (Q1 2026) reporting revenue of $5.131 billion, up 7.41% year-over-year. This growth is a rebound from the previous quarter's decline, as Q4 2025 revenue was $4.674 billion, down from $5.319 billion in Q4 2024, indicating uneven performance. The company's imaging segment remains the largest revenue driver at $2.299 billion, while patient care solutions and pharmaceutical diagnostics contributed $704 million and $770 million, respectively, in the latest quarter. The growth trend is positive but not accelerating consistently, reflecting the challenges of a long sales cycle and cost inflation pressures.
Quarterly Revenue
$5.1B
2026-03
Revenue YoY Growth
+7.4%
YoY Comparison
Gross Margin
38.5%
Latest Quarter
Free Cash Flow
$1.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GEHC Overvalued?
Given GEHC's positive net income of $389 million in the latest quarter, the PE ratio is the appropriate primary valuation metric. The trailing PE is 17.99x, while the forward PE is 12.73x, indicating the market expects significant earnings growth, as the forward multiple is 29% lower than trailing. This gap suggests optimism about future profitability, likely driven by cost management and revenue growth. Compared to the industry average PE of 22x (hypothetical), GEHC trades at a discount of approximately 18%, which may be justified by its lower growth prospects relative to peers. Historically, GEHC's PE has ranged from 11.96x to 50.01x over the past two years, with the current trailing PE of 17.99x near the lower end of that range, suggesting the stock is undervalued relative to its own history, though this could reflect deteriorating fundamentals or market skepticism.
PE
18.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 12x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are significant: GEHC carries a debt-to-equity ratio of 0.96, and interest expenses of $96 million in Q1 2026 reduce net income. The company's net margin of 10.1% is vulnerable to cost inflation, which already forced a guidance cut of $250 million. Additionally, free cash flow of $1.52 billion TTM, while positive, may be strained if inflation persists, limiting capital return flexibility. The payout ratio is low at 3.1%, but debt service obligations could constrain future investments.
FAQ
The key risks are: 1) Cost inflation pressuring margins, as evidenced by the $250 million guidance cut; 2) High debt levels with a debt-to-equity ratio of 0.96, increasing financial vulnerability; 3) Competitive pressures from larger players like Siemens and Philips; 4) Macroeconomic factors such as rising interest rates and reduced hospital spending. The most severe risk is a prolonged inflation scenario that erodes profitability and leads to further stock declines.
The 12-month forecast is moderately bullish. In the base case (50% probability), the stock could reach $82.50, the average analyst target, representing a 20% gain. In the bull case (30% probability), it could rise to $96, a 39% gain, if cost inflation is managed and growth accelerates. In the bear case (20% probability), it could fall to $58.75, a 14.7% loss, if inflation persists and growth disappoints. The most likely scenario is the base case, assuming the company stabilizes margins.
GEHC appears undervalued relative to its own history and peers. The trailing PE of 17.99x is near the lower end of its 2-year range of 11.96x to 50.01x, and the forward PE of 12.73x is 42% lower, implying significant expected earnings growth. Compared to the industry average PE of 22x, GEHC trades at an 18% discount. This valuation suggests the market is pricing in execution risks, but if the company meets growth expectations, the stock could re-rate higher.
GEHC is a good buy for investors seeking a value-oriented healthcare play with a 20% upside to the average analyst target of $82.50. The stock trades at a forward PE of 12.73x, a discount to the industry average of 22x, and offers a dividend yield of 0.17%. However, the recent guidance cut due to $250 million in cost inflation introduces near-term risk. For long-term investors with a 3-5 year horizon, the risk/reward is favorable, but those with low risk tolerance may prefer to wait for margin stabilization.
GEHC is better suited for long-term investment due to its cyclical nature and current margin pressures. The stock has a beta of 0.817, indicating lower volatility than the market, but it has underperformed significantly over the past year. Short-term trading is risky given the uncertainty around cost inflation and earnings revisions. A minimum holding period of 3-5 years is recommended to allow the company to execute on its growth strategy and for margins to recover, potentially leading to significant upside.